Results 31 to 40 of about 184,390 (149)

Rapid response of advanced squamous non-small cell lung cancer with thrombocytopenia after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells

Frontiers in Immunology, 2015
We present the first clinical evidence of advanced squamous non-small cell lung cancer with severe thrombocytopenia showing dramatic improvement after first-line treatment with pembrolizumab plus cytokine-induced killer cells.
Zhenzhen eHui, Xinwei eZhang, Baozhu eRen, Runmei eLi, Xiubao eRen   +4 more
doaj   +1 more source

Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer

Frontiers in Immunology, 2022
Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal ...
Xinyi Yang, Xinyi Yang, Desheng Weng, Desheng Weng, Qiuzhong Pan, Qiuzhong Pan, Tong Xiang, Tong Xiang, Chaopin Yang, Chaopin Yang, Zhengrong Wu, Minxing Li, Minxing Li, Songzuo Xie, Songzuo Xie, Yan Tang, Yan Tang, Jianchuan Xia, Jianchuan Xia, Jingjing Zhao, Jingjing Zhao   +20 more
doaj   +1 more source

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Clinical & Translational Immunology, 2021
Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and a low ...
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia   +29 more
doaj   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy

Frontiers in Immunology, 2017
Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD3+CD56+ natural killer T cells, which can be easily expanded in vitro from peripheral blood mononuclear cells.
Xingchun Gao, Xingchun Gao, Xingchun Gao, Yajing Mi, Yajing Mi, Na Guo, Hao Xu, Lixian Xu, Xingchun Gou, Weilin Jin, Weilin Jin, Weilin Jin   +11 more
doaj   +1 more source

Advances in research based on antibody-cell conjugation

Frontiers in Immunology, 2023
Antibody-cell conjugation (ACC) technology is a new research direction in medicine and biotechnology in recent years. The concept of ACC was proposed by Hsiao et al.
Xiaoxuan Ma, Jian Jiang, Xiaoye An, Wanting Zu, Chi Ma, Zhuo Zhang, Yaci Lu, Lijing Zhao, Lisheng Wang   +8 more
doaj   +1 more source

NCR+ ILC3 maintain larger STAT4 reservoir via T-BET to regulate type 1 features upon IL-23 stimulation in mice [PDF]

, 2018
Innate lymphoid cells (ILCs) producing IL-22 and/or IL-17, designated as ILC3, comprise a heterogeneous subset of cells involved in regulation of gut barrier homeostasis and inflammation.
Kanno, Yuka, Mikami, Yohei, O'Shea, John J, Santoni, Angela, SCARNO, GIANLUCA, Sciumè, Giuseppe, Shih, Han-Yu, Zitti, Beatrice   +7 more
core   +1 more source

Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells

Frontiers in Immunology, 2022
CD3+/CD56+ Natural killer (NK) cell-like T-cells (NKT-like cells) represent <5% of blood lymphocytes, display a cytotoxic phenotype, and can kill various cancers. NKT-like cells can be expanded ex vivo into cytokine-induced killer (CIK) cells, however
Tiffany M. Zúñiga, Forrest L. Baker, Kyle A. Smith, Helena Batatinha, Branden Lau, Michael P. Gustafson, Emmanuel Katsanis, Emmanuel Katsanis, Emmanuel Katsanis, Emmanuel Katsanis, Emmanuel Katsanis, Richard J. Simpson, Richard J. Simpson, Richard J. Simpson, Richard J. Simpson   +14 more
doaj   +1 more source

Immune cells and preterm labour:do invariant NKT cells hold the key? [PDF]

, 2015
We have developed our original made-to-measure (M2M) algorithm, PRIMAL, with the aim of modelling the Galactic disc from upcoming Gaia data. From a Milky Way like N-body disc galaxy simulation, we have created mock Gaia data using M0III stars as tracers,
Rinaldi, S F, Rossi, A G, Saunders, Philippa, Norman, J E   +3 more
core   +3 more sources

Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer

Frontiers in Medicine, 2023
This study aimed to characterize the safety and efficacy of DC-CIK therapy in two patients with previously treated chronic lymphocytic leukemia or peritoneal cancer, respectively.
Brian Mehling, DongCheng Wu, Ellen O’Gorman, Daniel Sheridan, Doreen Santora, Renata Mihályová   +5 more
doaj   +1 more source